The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Statistical validation of intermediate endpoints for chronic diseases
Abstract
We discuss the implementation of a criterion due to Prentice for the statistical validation of intermediate endpoints for chronic disease. The criterion involves examining in a cohort or intervention study whether an exposure or intervention effect, adjusted for the intermediate endpoint, is reduced to zero. For example, to examine whether serum cholesterol level is an intermediate endpoint for coronary heart disease (CHD), we may investigate the effect of the cholesterol lowering drug cholestyramine on CHD incidence adjusted for serum cholesterol levels. We show that use of this criterion will usually demand some form of model selection. When the unadjusted exposure or treatment effect is less than four times its standard error, the analysis can usually lead only to a weak form of validation, a conclusion that the data are not inconsistent with the validation criterion. More significant unadjusted exposure effects offer the potential for stronger types of validation statement such as ‘the intermediate endpoint explains at least 50 per cent (or 75 per cent) of the exposure effect’.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Surrogate endpoints in clinical trials: Cardiovascular diseases
Wittes, J., Lakatos, E., & Probstfield, J. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080405 · Cited by 247
On errors-in-variables for binary regression models
CARROLL, R. J., SPIEGELMAN, C. H., LAN, K. K. G., BAILEY, K. T., & ABBOTT, R. D. (1984) · Biometrika · doi:10.1093/biomet/71.1.19 · Cited by 219
Surrogate endpoints in clinical trials: Cancer
Ellenberg, S. S., & Hamilton, J. M. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080404 · Cited by 166
Validation of Intermediate End Points in Cancer Research
Schatzkin, A. G., Freedman, L. S., Schiffman, M. H., & Dawsey, S. M. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.22.1746 · Cited by 153
Self-citationSurrogate end points in clinical trials.
Ellenberg, S. S. (1991) · BMJ · doi:10.1136/bmj.302.6768.63 · Cited by 66
Machado, S. G., Gail, M. H., & Ellenberg, S. S. (1990) · PubMed · Cited by 46
Surrogate endpoints in clinical trials: Ophthalmologic disorders
Hillis, A., & SEIGEL, D. G. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080406 · Cited by 46
Cited by
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Equivalence of the Mediation, Confounding and Suppression Effect
MacKinnon, D. P., Krull, J. L., & Lockwood, C. M. (2000) · Prevention Science · doi:10.1023/a:1026595011371 · Cited by 4,188
A general approach to causal mediation analysis.
Imai, K., Keele, L., & Tingley, D. (2010) · Psychological Methods · doi:10.1037/a0020761 · Cited by 4,143
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Principal Stratification in Causal Inference
Frangakis, C. E., & Rubin, D. B. (2002) · Biometrics · doi:10.1111/j.0006-341x.2002.00021.x · Cited by 1,511
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Odds Ratios for Mediation Analysis for a Dichotomous Outcome
VanderWeele, T. J., & Vansteelandt, S. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq332 · Cited by 809
Sperling, R. S., Shapiro, D. E., Coombs, R. W., Todd, J. A., Herman, S. A., McSherry, G. D., O'Sullivan, M. J., Van Dyke, R. B., Jimenez, E., Rouzioux, C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352201 · Cited by 803
Shaffer, N., Chuachoowong, R., Mock, P. A., Bhadrakom, C., Siriwasin, W., Young, N. L., Chotpitayasunondh, T., Chearskul, S., Roongpisuthipong, A., Chinayon, P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10411-7 · Cited by 785
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Parsons, P. E., Eisner, M. D., Thompson, B. T., Matthay, M. A., Ancukiewicz, M., Bernard, G. R., & Wheeler, A. P. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000149854.61192.dc · Cited by 723
Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS
O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., & Hamilton, J. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602153340703 · Cited by 720
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
The validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 624
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588
Older Women With Diabetes Have a Higher Risk of Falls
Schwartz, A. V., Hillier, T. A., Sellmeyer, D. E., Resnick, H. E., Gregg, E., Ensrud, K. E., Schreiner, P. J., Margolis, K. L., Cauley, J. A., Nevitt, M. C., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1749 · Cited by 576
ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER
LIN, D. Y., FLEMING, T. R., & DE GRUTTOLA, V. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1 · Cited by 520
Sarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M., & Harper, K. D. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.1 · Cited by 442
Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials
De Gruttola, V. G., Clax, P., DeMets, D. L., Downing, G. J., Ellenberg, S. S., Friedman, L., Gail, M. H., Prentice, R., Wittes, J., & Zeger, S. L. (2001) · Controlled Clinical Trials · doi:10.1016/s0197-2456(01)00153-2 · Cited by 427
Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
Buyse, M., & Molenberghs, G. (1998) · Biometrics · doi:10.2307/2533853 · Cited by 425
Classification of osteoarthritis biomarkers: a proposed approach
Bauer, D. C., Hunter, D. J., Abramson, S. B., Attur, M., Corr, M., Felson, D., Heinegård, D., Jordan, J. M., Kepler, T. B., Lane, N. E., et al. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.04.001 · Cited by 405
Prasad, V., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 403
Coudeville, L., Bailleux, F., Riche, B., Megas, F., Andre, P., & Ecochard, R. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-18 · Cited by 374
Lahm, T., Douglas, I. S., Archer, S. L., Bogaard, H. J., Chesler, N. C., Haddad, F., Hemnes, A. R., Kawut, S. M., Kline, J. A., Kolb, T. M., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1160st · Cited by 343
Progression-Free Survival: Meaningful or Simply Measurable?
Booth, C. M., & Eisenhauer, E. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7571 · Cited by 324
Shamji, M. H., Ljørring, C., Francis, J. N., A Calderon, M., Larché, M., Kimber, I., Frew, A. J., Ipsen, H., Lund, K., Würtzen, P. A., et al. (2012) · Allergy · doi:10.1111/j.1398-9995.2011.02745.x · Cited by 297
(2010) · Journal of Wound Care · doi:10.12968/jowc.2010.19.6.48471 · Cited by 292
de Grooth, H.-J., Geenen, I. L., Girbes, A. R., Vincent, J.-L., Parienti, J.-J., & Oudemans-van Straaten, H. M. (2017) · Critical Care · doi:10.1186/s13054-017-1609-1 · Cited by 286
Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., & Eisenberger, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4769 · Cited by 275
Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16
Petrylak, D. P., Ankerst, D. P., Jiang, C. S., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Kohli, M., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj129 · Cited by 275
The intermediate endpoint effect in logistic and probit regression
MacKinnon, D. P., Lockwood, C. M., Brown, C. H., Wang, W., & Hoffman, J. M. (2007) · Clinical Trials · doi:10.1177/1740774507083434 · Cited by 261
Low Heart Rate Variability and the Effect of Depression on Post–Myocardial Infarction Mortality
Carney, R. M., Blumenthal, J. A., Freedland, K. E., Stein, P. K., Howells, W. B., Berkman, L. F., Watkins, L. L., Czajkowski, S. M., Hayano, J., Domitrovich, P. P., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.13.1486 · Cited by 258
Tuberculosis and Poverty: Why Are the Poor at Greater Risk in India?
Oxlade, O., & Murray, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047533 · Cited by 257
Kanaya, A. M., Barrett-Connor, E., Gildengorin, G., & Yaffe, K. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1327 · Cited by 255
Gabler, N. B., French, B., Strom, B. L., Palevsky, H. I., Taichman, D. B., Kawut, S. M., & Halpern, S. D. (2012) · Circulation · doi:10.1161/circulationaha.112.105890 · Cited by 255
Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A. H., Hague, W., Keech, A., Thompson, P., White, H., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 254
Ditlevsen, S., Christensen, U., Lynch, J., Damsgaard, M. T., & Keiding, N. (2005) · Epidemiology · doi:10.1097/01.ede.0000147107.76079.07 · Cited by 246
Alexopoulos, G. S., Raue, P. J., Kiosses, D. N., Mackin, R. S., Kanellopoulos, D., McCulloch, C., & Areán, P. A. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.177 · Cited by 199
“Proportion explained”: a causal interpretation for standard measures of indirect effect?
Hafeman, D. M. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp283 · Cited by 98
Statistical assessment of mediational effects for logistic mediational models
Huang, B., Sivaganesan, S., Succop, P., & Goodman, E. (2004) · Statistics in Medicine · doi:10.1002/sim.1847 · Cited by 89
Developing retinal biomarkers of neurological disease: an analytical perspective
MacCormick, I. J., Czanner, G., & Faragher, B. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.17 · Cited by 47
Metadata
- Authors
- Freedman, L. S., Graubard, B. I., & Schatzkin, A.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 1992-01
- Volume
- 11
- Issue
- 2
- Pages
- 167-178
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2142257518
- Cited by
- 651
- References
- 11
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.